Fink EC, McConkey M, Adams DN, et al. is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood. 2018;132(14):1535-1544. doi:10.1182/blood-2018-05-852798.
Gao X, Tao Y, Lamas V, et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature. 2018;553(7687):217-221. doi:10.1038/nature25164.
Danai LV, Babic A, Rosenthal MH, et al. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature. 2018;558(7711):600-604. doi:10.1038/s41586-018-0235-7.
Freitas CG, Lima SMF, Freire MS, et al. An Immunomodulatory Peptide Confers Protection in an Experimental Candidemia Murine Model. Antimicrob Agents Chemother. 2017;61(8). doi:10.1128/AAC.02518-16.
Yuskaitis CJ, Jones BM, Wolfson RL, et al. A mouse model of DEPDC5-related epilepsy: Neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility. Neurobiol Dis. 2018;111:91-101. doi:10.1016/j.nbd.2017.12.010.
Droujinine IA, Meyer AS, Wang D, et al. Proteomics of protein trafficking by in vivo tissue-specific labeling. Nat Commun. 2021;12(1):2382. doi:10.1038/s41467-021-22599-x.